Hyoscine Butylbromide for Prevention of Bradycardia During Cesarean Section

PHASE4CompletedINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

October 10, 2019

Primary Completion Date

February 25, 2020

Study Completion Date

February 25, 2020

Conditions
BradycardiaSpinal Anesthetics Causing Adverse Effects in Therapeutic UseCesarean Section Complications
Interventions
DRUG

Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule

Patients will receive IV study solution which is hyoscine butylbromide 20 mg in 1 ml one minute after spinal anaesthesia

OTHER

Normal saline

Patients will receive 1 ml of IV normal saline as a placebo one minute after spinal anesthesia

Trial Locations (1)

11111

Assiut University hospital, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT04069078 - Hyoscine Butylbromide for Prevention of Bradycardia During Cesarean Section | Biotech Hunter | Biotech Hunter